Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab Monotherapy in Adolescents with Moderate-to-Severe Atopic Dermatitis
NCT03526861Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Jun 2018
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of tralokinumab in atopic dermatitis (AD) (8 arms), sponsored by LEO Pharma. Primary endpoints: Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 52 and Subjects With at Least 75% Reduction in Eczema Area and Severity Index at Week 52. Started Jun 2018; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03526861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03526861.